MovDisordV3, Main, Merge, bibRecord, 005336

End-of-dose akinesia after a single intravenous infusion of the dopaminergic agonist piribedil in Parkinson's disease patients : A pharmacokinetic/pharmacodynamic, randomized, double-blind study

Identifieur interne : 005336 ( Main/Merge ); précédent : 005335; suivant : 005337

End-of-dose akinesia after a single intravenous infusion of the dopaminergic agonist piribedil in Parkinson's disease patients : A pharmacokinetic/pharmacodynamic, randomized, double-blind study

Auteurs : Nicolas Simon [France] ; Joëlle Micallef [France] ; Jean-Charles Reynier [France] ; Monique Lesourd [France] ; Tatiana Witjas [France] ; André Alicherif [France] ; Jean-Philippe Azulay [France] ; Olivier Blin [France]

Source :

Movement disorders [ 0885-3185 ] ; 2005.

RBID : Pascal:05-0387232

Descripteurs français

Pascal (Inist)
- Système nerveux pathologie, Akinésie, Parkinson maladie, Dose unique, Voie intraveineuse, Piribédil, Homme, Pharmacocinétique, Etude double insu, Pharmacodynamie.
Wicri :
- topic : Homme.

English descriptors

KwdEn :
- Akinesia, Double blind study, Human, Intravenous administration, Nervous system diseases, Parkinson disease, Pharmacodynamics, Pharmacokinetics, Piribedil, Single dose.

Abstract

This randomized, double-blind trial was designed to define the possible relationship between piribedil plasma concentrations and the decrease of the Unified Parkinson's Disease Rating Scale (UPDRS) motor score or the switch from off to on state after single intravenous infusion. Ten fluctuating patients with idiopathic Parkinson's disease (PD) received escalating doses of piribedil (2-16 mg) and placebo. Starting from 2 mg, piribedil was effective in reducing the motor deficit (UPDRS, motor score) including akinesia at the first evaluation time point of 15 minutes, and in reversing off state of 7 of 10 patients. The doses were equally effective, although the effect was more sustained with the highest dose of 16 mg. Piribedil was well tolerated up to a 16-mg dose and pharmacokinetics were linear up to the 16-mg dose. Plasma levels of piribedil were not correlated to the motor score improvement or switch from off→on. In conclusion, a short single infusion of piribedil at 2 to 16 mg was safe and effective in improving motor symptoms, including akinesia, of fluctuating PD patients.

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: 001E31
to stream PascalFrancis, to step Curation: 000E90
to stream PascalFrancis, to step Checkpoint: 001E58

Links to Exploration step

Pascal:05-0387232

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">End-of-dose akinesia after a single intravenous infusion of the dopaminergic agonist piribedil in Parkinson's disease patients : A pharmacokinetic/pharmacodynamic, randomized, double-blind study</title>
<author><name sortKey="Simon, Nicolas" sort="Simon, Nicolas" uniqKey="Simon N" first="Nicolas" last="Simon">Nicolas Simon</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Laboratoire de Pharmacologie Medicale et Clinique, Centre Hospitalier Universitaire Timone</s1>
<s2>Marseille</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><settlement type="city">Marseille</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Micallef, Joelle" sort="Micallef, Joelle" uniqKey="Micallef J" first="Joëlle" last="Micallef">Joëlle Micallef</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>CPCET, Centre Hospitalier Universitaire Timone, Institut des Neurosciences Cognitives de la Mediterran, CNRS-Universite de la Méditerranée</s1>
<s2>Marseille</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><settlement type="city">Marseille</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Reynier, Jean Charles" sort="Reynier, Jean Charles" uniqKey="Reynier J" first="Jean-Charles" last="Reynier">Jean-Charles Reynier</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>CPCET, Centre Hospitalier Universitaire Timone, Institut des Neurosciences Cognitives de la Mediterran, CNRS-Universite de la Méditerranée</s1>
<s2>Marseille</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><settlement type="city">Marseille</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Lesourd, Monique" sort="Lesourd, Monique" uniqKey="Lesourd M" first="Monique" last="Lesourd">Monique Lesourd</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Institut de Recherches Internationales Servier</s1>
<s2>Courbevoie</s2>
<s3>FRA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>France</country>
<wicri:noRegion>Courbevoie</wicri:noRegion>
<wicri:noRegion>Institut de Recherches Internationales Servier</wicri:noRegion>
<wicri:noRegion>Institut de Recherches Internationales Servier</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Witjas, Tatiana" sort="Witjas, Tatiana" uniqKey="Witjas T" first="Tatiana" last="Witjas">Tatiana Witjas</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>CPCET, Centre Hospitalier Universitaire Timone, Institut des Neurosciences Cognitives de la Mediterran, CNRS-Universite de la Méditerranée</s1>
<s2>Marseille</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><settlement type="city">Marseille</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Alicherif, Andre" sort="Alicherif, Andre" uniqKey="Alicherif A" first="André" last="Alicherif">André Alicherif</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>CPCET, Centre Hospitalier Universitaire Timone, Institut des Neurosciences Cognitives de la Mediterran, CNRS-Universite de la Méditerranée</s1>
<s2>Marseille</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><settlement type="city">Marseille</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Azulay, Jean Philippe" sort="Azulay, Jean Philippe" uniqKey="Azulay J" first="Jean-Philippe" last="Azulay">Jean-Philippe Azulay</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>CPCET, Centre Hospitalier Universitaire Timone, Institut des Neurosciences Cognitives de la Mediterran, CNRS-Universite de la Méditerranée</s1>
<s2>Marseille</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><settlement type="city">Marseille</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Blin, Olivier" sort="Blin, Olivier" uniqKey="Blin O" first="Olivier" last="Blin">Olivier Blin</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>CPCET, Centre Hospitalier Universitaire Timone, Institut des Neurosciences Cognitives de la Mediterran, CNRS-Universite de la Méditerranée</s1>
<s2>Marseille</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><settlement type="city">Marseille</settlement>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">05-0387232</idno>
<date when="2005">2005</date>
<idno type="stanalyst">PASCAL 05-0387232 INIST</idno>
<idno type="RBID">Pascal:05-0387232</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001E31</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000E90</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">001E58</idno>
<idno type="wicri:doubleKey">0885-3185:2005:Simon N:end:of:dose</idno>
<idno type="wicri:Area/Main/Merge">005336</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">End-of-dose akinesia after a single intravenous infusion of the dopaminergic agonist piribedil in Parkinson's disease patients : A pharmacokinetic/pharmacodynamic, randomized, double-blind study</title>
<author><name sortKey="Simon, Nicolas" sort="Simon, Nicolas" uniqKey="Simon N" first="Nicolas" last="Simon">Nicolas Simon</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Laboratoire de Pharmacologie Medicale et Clinique, Centre Hospitalier Universitaire Timone</s1>
<s2>Marseille</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><settlement type="city">Marseille</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Micallef, Joelle" sort="Micallef, Joelle" uniqKey="Micallef J" first="Joëlle" last="Micallef">Joëlle Micallef</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>CPCET, Centre Hospitalier Universitaire Timone, Institut des Neurosciences Cognitives de la Mediterran, CNRS-Universite de la Méditerranée</s1>
<s2>Marseille</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><settlement type="city">Marseille</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Reynier, Jean Charles" sort="Reynier, Jean Charles" uniqKey="Reynier J" first="Jean-Charles" last="Reynier">Jean-Charles Reynier</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>CPCET, Centre Hospitalier Universitaire Timone, Institut des Neurosciences Cognitives de la Mediterran, CNRS-Universite de la Méditerranée</s1>
<s2>Marseille</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><settlement type="city">Marseille</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Lesourd, Monique" sort="Lesourd, Monique" uniqKey="Lesourd M" first="Monique" last="Lesourd">Monique Lesourd</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Institut de Recherches Internationales Servier</s1>
<s2>Courbevoie</s2>
<s3>FRA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>France</country>
<wicri:noRegion>Courbevoie</wicri:noRegion>
<wicri:noRegion>Institut de Recherches Internationales Servier</wicri:noRegion>
<wicri:noRegion>Institut de Recherches Internationales Servier</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Witjas, Tatiana" sort="Witjas, Tatiana" uniqKey="Witjas T" first="Tatiana" last="Witjas">Tatiana Witjas</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>CPCET, Centre Hospitalier Universitaire Timone, Institut des Neurosciences Cognitives de la Mediterran, CNRS-Universite de la Méditerranée</s1>
<s2>Marseille</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><settlement type="city">Marseille</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Alicherif, Andre" sort="Alicherif, Andre" uniqKey="Alicherif A" first="André" last="Alicherif">André Alicherif</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>CPCET, Centre Hospitalier Universitaire Timone, Institut des Neurosciences Cognitives de la Mediterran, CNRS-Universite de la Méditerranée</s1>
<s2>Marseille</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><settlement type="city">Marseille</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Azulay, Jean Philippe" sort="Azulay, Jean Philippe" uniqKey="Azulay J" first="Jean-Philippe" last="Azulay">Jean-Philippe Azulay</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>CPCET, Centre Hospitalier Universitaire Timone, Institut des Neurosciences Cognitives de la Mediterran, CNRS-Universite de la Méditerranée</s1>
<s2>Marseille</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><settlement type="city">Marseille</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Blin, Olivier" sort="Blin, Olivier" uniqKey="Blin O" first="Olivier" last="Blin">Olivier Blin</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>CPCET, Centre Hospitalier Universitaire Timone, Institut des Neurosciences Cognitives de la Mediterran, CNRS-Universite de la Méditerranée</s1>
<s2>Marseille</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><settlement type="city">Marseille</settlement>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2005">2005</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Akinesia</term>
<term>Double blind study</term>
<term>Human</term>
<term>Intravenous administration</term>
<term>Nervous system diseases</term>
<term>Parkinson disease</term>
<term>Pharmacodynamics</term>
<term>Pharmacokinetics</term>
<term>Piribedil</term>
<term>Single dose</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Système nerveux pathologie</term>
<term>Akinésie</term>
<term>Parkinson maladie</term>
<term>Dose unique</term>
<term>Voie intraveineuse</term>
<term>Piribédil</term>
<term>Homme</term>
<term>Pharmacocinétique</term>
<term>Etude double insu</term>
<term>Pharmacodynamie</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">This randomized, double-blind trial was designed to define the possible relationship between piribedil plasma concentrations and the decrease of the Unified Parkinson's Disease Rating Scale (UPDRS) motor score or the switch from off to on state after single intravenous infusion. Ten fluctuating patients with idiopathic Parkinson's disease (PD) received escalating doses of piribedil (2-16 mg) and placebo. Starting from 2 mg, piribedil was effective in reducing the motor deficit (UPDRS, motor score) including akinesia at the first evaluation time point of 15 minutes, and in reversing off state of 7 of 10 patients. The doses were equally effective, although the effect was more sustained with the highest dose of 16 mg. Piribedil was well tolerated up to a 16-mg dose and pharmacokinetics were linear up to the 16-mg dose. Plasma levels of piribedil were not correlated to the motor score improvement or switch from off→on. In conclusion, a short single infusion of piribedil at 2 to 16 mg was safe and effective in improving motor symptoms, including akinesia, of fluctuating PD patients.</div>
</front>
</TEI>
<affiliations><list><country><li>France</li>
</country>
<settlement><li>Marseille</li>
</settlement>
</list>
<tree><country name="France"><noRegion><name sortKey="Simon, Nicolas" sort="Simon, Nicolas" uniqKey="Simon N" first="Nicolas" last="Simon">Nicolas Simon</name>
</noRegion>
<name sortKey="Alicherif, Andre" sort="Alicherif, Andre" uniqKey="Alicherif A" first="André" last="Alicherif">André Alicherif</name>
<name sortKey="Azulay, Jean Philippe" sort="Azulay, Jean Philippe" uniqKey="Azulay J" first="Jean-Philippe" last="Azulay">Jean-Philippe Azulay</name>
<name sortKey="Blin, Olivier" sort="Blin, Olivier" uniqKey="Blin O" first="Olivier" last="Blin">Olivier Blin</name>
<name sortKey="Lesourd, Monique" sort="Lesourd, Monique" uniqKey="Lesourd M" first="Monique" last="Lesourd">Monique Lesourd</name>
<name sortKey="Micallef, Joelle" sort="Micallef, Joelle" uniqKey="Micallef J" first="Joëlle" last="Micallef">Joëlle Micallef</name>
<name sortKey="Reynier, Jean Charles" sort="Reynier, Jean Charles" uniqKey="Reynier J" first="Jean-Charles" last="Reynier">Jean-Charles Reynier</name>
<name sortKey="Witjas, Tatiana" sort="Witjas, Tatiana" uniqKey="Witjas T" first="Tatiana" last="Witjas">Tatiana Witjas</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Merge

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 005336 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Merge/biblio.hfd -nk 005336 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Main
   |étape=   Merge
   |type=    RBID
   |clé=     Pascal:05-0387232
   |texte=   End-of-dose akinesia after a single intravenous infusion of the dopaminergic agonist piribedil in Parkinson's disease patients : A pharmacokinetic/pharmacodynamic, randomized, double-blind study
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

End-of-dose akinesia after a single intravenous infusion of the dopaminergic agonist piribedil in Parkinson's disease patients : A pharmacokinetic/pharmacodynamic, randomized, double-blind study

End-of-dose akinesia after a single intravenous infusion of the dopaminergic agonist piribedil in Parkinson's disease patients : A pharmacokinetic/pharmacodynamic, randomized, double-blind study

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri